Search results for "Drug agency"

showing 2 items of 2 documents

Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience

2019

Abstract Aims In 2017 the Italian Drug Agency (Agenzia Italiana del Farmaco, AIFA) revised the criteria for access to therapy for patients with chronic hepatitis C as part of a three-year plan to eradicate HCV. We conducted a Delphi study to determine strategies to identify and treat patients with HCV and to develop through a shared pathway, a model to manage patient referral and optimize prescription center capacity with the overall aim of increasing access to therapy. Methods The process took place in two phases – Phase I (January 2017), before the criteria for treatment of HCV were revised and Phase II (May 2017) when AIFA developed a framework for the eradication of HCV infection in Ita…

AdultMalemedicine.medical_specialtyDelphi TechniqueGeneral PracticeDelphi methodDelphi methodAntiviral AgentsDrug PrescriptionsHealth Services AccessibilityMedication AdherencemodelsPatient referralTreatment targetsChronic hepatitismedicineHumansdelphi method; direct-acting antivirals; disease eradication; hepatitis c virus; adult; aged; antiviral agents; disease eradication; drug prescriptions; female; general practice; health care surveys; health services accessibility; hepatitis c chronic; humans; italy; male; medication adherence; middle aged; models theoretical; quality Improvement; referral and consultation; delphi techniquehepatitis cMedical prescriptiontheoreticalReferral and Consultationdirect-acting antiviralsAgedHepatitisdirect-acting antiviralHepatologyDisease Eradicationbusiness.industryHepatitis C virusGastroenterologyDrug agencyHepatitis C ChronicMiddle AgedModels Theoreticalmedicine.diseaseQuality ImprovementchronicItalyHealth Care SurveysFamily medicineFemaledisease eradicationbusiness
researchProduct

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

2009

At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients t…

AdultMalemedicine.medical_specialtyPediatricsNeurologyMultiple SclerosisPatient DropoutsDatabases FactualAlternative medicineDermatologyPharmacologyAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingMedicineHumansGlatiramer acetateMultiple sclerosis NatalizumabSurveillance programPharmacovigilancebusiness.industryMultiple sclerosisNatalizumabAntibodies MonoclonalDrug agencyGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingPsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYSettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerybusinessmedicine.drugFollow-Up StudiesNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct